Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis
This abstract from the 2017 American Society of Hematology Annual Meeting supports LCL161 as a potential promoter of apoptosis in patients with myelofibrosis, including those with JAK inhibitor–refractory disease.
Blood (ASH Abstract)
In The News
American Journal of Managed Care
In The Literature
American Journal of Hematology European Journal of Haematology